AstraZeneca just showed how fast an established cancer drug can achieve a crucial line extension.
Just two months after the pharma giant and its partners at Merck turned up at ESMO to tout some truly impressive detailed results for Lynparza as a frontline therapy for BRCA-mutated ovarian cancer, the agency has come through with a snap OK.
The key data point: A hazard ratio of 0.30, with a profound 70% reduction in risk of death. These days, the FDA is not reluctant to slap an OK on a cancer drug, and AstraZeneca’s R&D team has spent years working on an expanded market for the drug after winning the pioneering approval for a PARP inhibitor.
GSK’s recent arrival on the scene with a buyout for a now shrunken PARP rival has underscored the lead that AstraZeneca and Merck have built up here. And shares of Clovis declined 6% after the news, which further overshadowed its PARP Rubraca.
In the SOLO-1 study 60% of the women receiving the drug were progression-free at 3 years, compared to less than half that in the placebo group.
AstraZeneca’s success with Lynparza and Tagrisso, with early inroads involving Imfinzi, have helped pave a long-awaited turnaround for the company, which has suffered through a dramatic onslaught of generic competition as their franchise drugs lost patent protection. And the FDA, which has signaled its readiness to speed up the game of R&D, has wasted no time in helping them swiftly advance.
“SOLO-1 is truly a landmark trial in gynecologic cancer.” said Kathleen Moore, the co-principal investigator.”This approval will likely change the way we treat women with BRCA-mutated advanced ovarian cancer. The ability to offer this important first-line maintenance treatment option to eligible patients may slow down or even stop the natural course of disease progression.”
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,100+ biopharma pros who read Endpoints News by email every day.Free Subscription